ArticleNature2024
Dietary fructose enhances tumour growth indirectly via interorgan lipid transfer.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Spatiotemporal dynamics of the host-tumor metabolic interface: Implications for precision nutritional oncology.Genes & diseases · 2026Review
- Host metadherin coordinates hepatic lipid metabolism and CD8Cell metabolism · 2026Article
- Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Endurance exercise elicits a hepatic memory associated with improved metabolic function and protein secretion.Molecular metabolism · 2026Article
- Fructose directly remodels the translocase of the outer membrane to impair oxidative phosphorylation in podocytes.Signal transduction and targeted therapy · 2026Article
- Metabolic adaptations of the tumor macroenvironment and their role in cancer progression and survivorship.Genes & development · 2026Review
- The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.Nature aging · 2026Article
- Harnessing probiotics to combat nonylphenol toxicity: a multiomics approach of gut microbiome remodelling in Silurus meridionalis.BMC genomics · 2026Article
- Substrate supply, compartmentation, and utilization in hepatic de novo lipogenesis.Trends in endocrinology and metabolism: TEM · 2026Review
- Intestinal fructose metabolism drives unsaturated fat absorption and synergizes with GLP-1 receptor agonism to promote weight loss.bioRxiv : the preprint server for biology · 2026Article
- Fructose 1-phosphate inhibits mannose phosphate isomerase to suppress hepatocellular carcinogenesis.Signal transduction and targeted therapy · 2026Article
- Fructose: metabolic signal and modern hazard.Nature metabolism · 2026Review
- Decoding cancer across scales with metabolomics.Nature reviews. Cancer · 2026Review
- Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models.Nature reviews. Gastroenterology & hepatology · 2026Review
- Article
- Rethinking the hepatoprotective potential of vegetarian diets in dysfunction-associated steatotic liver disease/metabolic-associated fatty liver disease: a critical narrative review.Frontiers in nutrition · 2026Review
- The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026Review
- Metabolic reprogramming as a driver of immune escape in melanoma: implications for immunotherapy.Frontiers in immunology · 2026Review
- Fructose metabolism as an adaptive survival axis in pancreatic cancer: mechanistic insights and therapeutic implications.Frontiers in medicine · 2026Review
- The interplay of dietary sugar, chronic inflammation, and bladder cancer: mechanistic insights, evidence, and prevention strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Ronald Fowle-GriderDepartment of Chemistry, Washington University, St Louis, MO, USA.
Joe L RowlesDepartment of Chemistry, Washington University, St Louis, MO, USA.
Isabel ShenDepartment of Chemistry, Washington University, St Louis, MO, USA.
Yahui WangDepartment of Chemistry, Washington University, St Louis, MO, USA.
Michaela Schwaiger-HaberDepartment of Chemistry, Washington University, St Louis, MO, USA.ORCID 0000-0002-2715-753X
Alden J DunhamDepartment of Chemistry, Washington University, St Louis, MO, USA.ORCID 0000-0001-5044-517X
Kay JayachandranDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA.
Matthew InkmanDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0001-5490-2374
Michael ZahnerDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA.
Fuad J NaserDepartment of Chemistry, Washington University, St Louis, MO, USA.
Madelyn M JackstadtDepartment of Chemistry, Washington University, St Louis, MO, USA.ORCID 0000-0001-5520-9213
Jonathan L SpaldingDepartment of Chemistry, Washington University, St Louis, MO, USA.
Sarah ChiangDepartment of Chemistry, Washington University, St Louis, MO, USA.
Kyle S McCommisDepartment of Biochemistry & Molecular Biology, Saint Louis University School of Medicine, St Louis, MO, USA.ORCID 0000-0003-2381-1589
Roland E DolleDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0001-5574-6019
Eva T KramerDivision of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0003-1363-3125
Sarah M ZimmermanDivision of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA.
George P SouroullasDivision of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0003-2196-8662
Brian N FinckDivision of Geriatrics and Nutritional Sciences, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0001-5411-3674
Leah P ShriverDepartment of Chemistry, Washington University, St Louis, MO, USA.
Charles K KaufmanDivision of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0003-3122-1677
Julie K SchwarzDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0003-2407-7531
Jin ZhangDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-9117-2793
Gary J PattiDepartment of Chemistry, Washington University, St Louis, MO, USA. gjpattij@wustl.edu.ORCID 0000-0002-3748-6193
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MWashington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 1999 to 2026
$30.2MWU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1MWashington University Institute of Clinical and Translational Sciences (TL1)TL1TR002344 · NCATS · WASHINGTON UNIVERSITY · PI Jay F. Piccirillo · 2017 to 2026
$8.5MWashington University (WU) ROBIN Center: MicroEnvironment and Tumor Effects Of Radiotherapy (METEOR)U54CA274318 · NCI · WASHINGTON UNIVERSITY · PI Clifford Grant Robinson · 2023 to 2026
$7.7MTARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITISR01DK104735 · NIDDK · WASHINGTON UNIVERSITY · PI FINCK, BRIAN N · 2015 to 2025
$7.1MDeveloping Metabolomic Technologies to Advance Environmental Exposure AnalysisR35ES028365 · NIEHS · WASHINGTON UNIVERSITY · PI PATTI, GARY J · 2017 to 2024
$5.9MMOLECULAR ONCOLOGY TRAINING GRANTT32CA113275 · NCI · WASHINGTON UNIVERSITY · PI Matthew J Walter · 2006 to 2026
$5.7MIntegrating multi-omics, imaging, and longitudinal data to predict radiation response in cervical cancerR01CA276955 · NCI · WASHINGTON UNIVERSITY · PI Jin Zhang · 2023 to 2026
$2.1MHPV genomic structure in cervical cancer radiation response and recurrence detectionR37CA279596 · NCI · WASHINGTON UNIVERSITY · PI Jin Zhang · 2023 to 2026
$2.0MHPV alternative splicing in cervical cancer radiation responseK22CA237839 · NCI · WASHINGTON UNIVERSITY · PI ZHANG, JIN · 2021 to 2023
$460kDeep learning in cervical cancer radiogenomicsR21CA264343 · NCI · WASHINGTON UNIVERSITY · PI ZHANG, JIN · 2022 to 2023
$401kNCATS NIH HHS TL1 TR002344NCI NIH HHS K22 CA237839NCI NIH HHS P30 CA091842NCI NIH HHS R21 CA264343NCI NIH HHS R37 CA279596NCI NIH HHS T32 CA113275NCI NIH HHS U54 CA274318NIDDK NIH HHS P30 DK056341NIDDK NIH HHS R01 DK104735NIEHS NIH HHS R35 ES028365
Abstract
Fructose consumption has increased considerably over the past five decades, largely due to the widespread use of high-fructose corn syrup as a sweetener
Indexed as
FructokinasesFructoseHepatocytesLysophosphatidylcholinesNeoplasmsAnimalsAzabicyclo CompoundsCell Line, TumorCoculture TechniquesDietDisease Models, AnimalFemaleHigh Fructose Corn SyrupHumansLipidsMiceAzabicyclo CompoundsFructokinasesFructoseHigh Fructose Corn SyrupketohexokinaseLipidsLysophosphatidylcholinesPF-06835919PhosphatidylcholinesPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.